New insights into the important roles of phase seperation in the targeted therapy of lung cancer

被引:9
|
作者
Zou, Ying [1 ]
Zheng, Hongmei [1 ]
Ning, Yue [1 ]
Yang, Yang [1 ]
Wen, Qiuyuan [1 ]
Fan, Songqing [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Pathol, Changsha 410011, Hunan, Peoples R China
来源
CELL AND BIOSCIENCE | 2023年 / 13卷 / 01期
关键词
Liquid-liquid phase separation; NSCLC; Targeted therapy; EGFR; YAP; SEPARATION; MECHANISMS; RECEPTOR; REPAIR; STAT3; YAP;
D O I
10.1186/s13578-023-01101-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lung cancer is a complex and heterogeneous disease characterized by abnormal growth and proliferation of lung cells. It is the leading cause of cancer-related deaths worldwide, accounting for approximately 18% of all cancer deaths. In recent years, targeted therapy has emerged as a promising approach to treat lung cancer, which involves the use of drugs that selectively target specific molecules or signaling pathways that are critical for the growth and survival of cancer cells. Liquid-liquid phase separation (LLPS) is a fundamental biological process that occurs when proteins and other biomolecules separate into distinct liquid phases in cells. LLPS is essential for various cellular functions, including the formation of membraneless organelles, the regulation of gene expression, and the response to stress and other stimuli. Recent studies have shown that LLPS plays a crucial role in targeted therapy of lung cancer, including the sequestration of oncogenic proteins and the development of LLPS-based drug delivery systems. Understanding the mechanisms of LLPS in these processes could provide insights into new therapeutic strategies to overcome drug resistance in lung cancer cells.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
    Zuan-Fu Lim
    Patrick C. Ma
    Journal of Hematology & Oncology, 12
  • [22] Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
    Lim, Zuan-Fu
    Ma, Patrick C.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [23] Targeted Therapy and Immunotherapy for Lung Cancer
    Naylor, Evan C.
    Desani, Jatin K.
    Chung, Paul K.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 25 (03) : 601 - +
  • [24] Targeted surgical therapy for lung cancer
    Stiles, Brendon M.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3904 - S3907
  • [25] Molecular targeted therapy for lung cancer
    Onn, A
    Herbst, RS
    LANCET, 2005, 366 (9496): : 1507 - 1508
  • [26] Molecular targeted therapy for lung cancer
    Nakaoku, Takashi
    Kohno, Takashi
    CANCER SCIENCE, 2018, 109 : 635 - 635
  • [27] Personalized Targeted Therapy for Lung Cancer
    Wu, Kehua
    House, Larry
    Liu, Wanqing
    Cho, William C. S.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2012, 13 (09) : 11471 - 11496
  • [28] New insights for IL-6 targeted therapy as an adjuvant treatment for non-small-cell lung cancer
    Zarogoulidis, Paul
    Yarmus, Lonny
    Zarogoulidis, Konstantinos
    THERAPEUTIC DELIVERY, 2013, 4 (10) : 1221 - 1223
  • [29] Targeted therapy for non-small-cell lung cancer: New insights into regulated cell death combined with immunotherapy
    Li, Shutong
    Wang, Aoxue
    Wu, Yongya
    He, Shengyuan
    Shuai, Wen
    Zhao, Min
    Zhu, Yumeng
    Hu, Xiuying
    Luo, Yubin
    Wang, Guan
    IMMUNOLOGICAL REVIEWS, 2024, 321 (01) : 300 - 334
  • [30] New insights into the roles of peroxiredoxins in cancer
    Liu, Yan
    Wang, Pu
    Hu, Weina
    Chen, Da
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 164